BACKGROUND: The aim of the present study was to define the proportion of different levels of family history in a cohort of consecutive breast cancer patients from the Stockholm region, and to assess whether familial breast cancer has phenotypic traits different from those of sporadic patients. METHODS: All incident breast cancer patients in a 19-month period were eligible for the study and 70% (489/696) participated. The family history and clinical parameters were obtained from questionnaires and medical records. RESULTS: In total 35% had a family history. Age at onset was 58.9 years in the familial group vs. 60.7 years in the sporadic patients (P = 0.14) and 8% of the familial patients had bilateral breast cancer compared to 4% in the sporadic group (P = 0.08). There were 31% node positive tumors in the sporadic group vs. 22% in the cases with family history (P = 0.04). Hormonal background, treatment and prognosis (median follow-up 4.7 years) were not related to family history. CONCLUSION: In addition to high-risk familial breast and breast-ovarian cancer, constituting about 10% of all breast cancer cases, another 25% of the breast cancer cases have a family history, a group hypothetically valuable for association studies on low-risk genes. In contrast to previous reports, we did not observe a relationship between family history and phenotypic traits. A possible explanation for this can be different study design. The considerable heterogeneity in familial breast cancer means that different criteria for familiality can influence the result. Furthermore, our study was prospective and population based and included paternal inheritance.
BACKGROUND: The aim of the present study was to define the proportion of different levels of family history in a cohort of consecutive breast cancerpatients from the Stockholm region, and to assess whether familial breast cancer has phenotypic traits different from those of sporadic patients. METHODS: All incident breast cancerpatients in a 19-month period were eligible for the study and 70% (489/696) participated. The family history and clinical parameters were obtained from questionnaires and medical records. RESULTS: In total 35% had a family history. Age at onset was 58.9 years in the familial group vs. 60.7 years in the sporadic patients (P = 0.14) and 8% of the familial patients had bilateral breast cancer compared to 4% in the sporadic group (P = 0.08). There were 31% node positive tumors in the sporadic group vs. 22% in the cases with family history (P = 0.04). Hormonal background, treatment and prognosis (median follow-up 4.7 years) were not related to family history. CONCLUSION: In addition to high-risk familial breast and breast-ovarian cancer, constituting about 10% of all breast cancer cases, another 25% of the breast cancer cases have a family history, a group hypothetically valuable for association studies on low-risk genes. In contrast to previous reports, we did not observe a relationship between family history and phenotypic traits. A possible explanation for this can be different study design. The considerable heterogeneity in familial breast cancer means that different criteria for familiality can influence the result. Furthermore, our study was prospective and population based and included paternal inheritance.
Authors: Antonio Russo; Andrea Herd-Smith; Donella Gestri; Simonetta Bianchi; Vanna Vezzosi; Marco Rosselli Del Turco; Gaetano Cardona Journal: Int J Cancer Date: 2002-05-20 Impact factor: 7.396
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: L A Boardman; S N Thibodeau; D J Schaid; N M Lindor; S K McDonnell; L J Burgart; D A Ahlquist; K C Podratz; M Pittelkow; L C Hartmann Journal: Ann Intern Med Date: 1998-06-01 Impact factor: 25.391
Authors: Meghan J Walker; Lucia Mirea; Kristine Cooper; Mitra Nabavi; Gord Glendon; Irene L Andrulis; Julia A Knight; Frances P O'Malley; Anna M Chiarelli Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Marijana Lijovic; Susan R Davis; Pam Fradkin; Jo Bradbury; Maria La China; Max Schwarz; Rory Wolfe; Helen Farrugia; Robin J Bell Journal: Fam Cancer Date: 2009-02-17 Impact factor: 2.375
Authors: Ellen T Chang; Roger L Milne; Kelly-Anne Phillips; Jane C Figueiredo; Meera Sangaramoorthy; Theresa H M Keegan; Irene L Andrulis; John L Hopper; Pamela J Goodwin; Frances P O'Malley; Nayana Weerasooriya; Carmel Apicella; Melissa C Southey; Michael L Friedlander; Graham G Giles; Alice S Whittemore; Dee W West; Esther M John Journal: Breast Cancer Res Treat Date: 2008-11-26 Impact factor: 4.872
Authors: Kristin Anderson; Patricia A Thompson; Betsy C Wertheim; Lorena Martin; Ian K Komenaka; Melissa Bondy; Adrian Daneri-Navarro; Maria Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Abenaa Brewster; Lisa Madlensky; Malaika Tobias; Loki Natarajan; María Elena Martínez Journal: Springerplus Date: 2014-12-11
Authors: Sepideh Saadatmand; Emiel J T Rutgers; Rob A E M Tollenaar; Hermien M Zonderland; Margreet G E M Ausems; Kristien B M I Keymeulen; Margreet S Schlooz-Vries; Linetta B Koppert; Eveline A M Heijnsdijk; Caroline Seynaeve; Cees Verhoef; Jan C Oosterwijk; Inge-Marie Obdeijn; Harry J de Koning; Madeleine M A Tilanus-Linthorst Journal: BMC Cancer Date: 2012-10-02 Impact factor: 4.430
Authors: B Song; S Margolin; J Skoglund; X Zhou; J Rantala; S Picelli; B Werelius; A Lindblom Journal: Br J Cancer Date: 2007-09-11 Impact factor: 7.640
Authors: Jennifer C Melvin; Wahyu Wulaningsih; Zac Hana; Arnie D Purushotham; Sarah E Pinder; Ian Fentiman; Cheryl Gillett; Anca Mera; Lars Holmberg; Mieke Van Hemelrijck Journal: Cancer Med Date: 2016-01-22 Impact factor: 4.452